BDX - Becton, Dickinson and Company
| Previous Close | 260.04 |
| Open | 261.17 |
| Bid | 261.81 x 800 |
| Ask | 261.87 x 800 |
| Day's Range | 260.41 - 262.26 |
| 52 Week Range | 191.53 - 263.37 |
| Volume | 752,131 |
| Avg. Volume | 938,648 |
| Market Cap | 70.046B |
| Beta | 1.09 |
| PE Ratio (TTM) | 107.33 |
| EPS (TTM) | 2.44 |
| Earnings Date | Oct 31, 2018 - Nov 5, 2018 |
| Forward Dividend & Yield | 3.00 (1.15%) |
| Ex-Dividend Date | 2018-09-06 |
| 1y Target Est | 268.07 |
Markit•8 hours agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
Market Realist•yesterdayWhat’s Driving the Growth in Thermo Fisher Scientific’s Segments?
Thermo Fisher Scientific (TMO) operates in four business segments. The Analytical Instruments segment provides instruments, software, and services for use in laboratory applications. The segment’s revenue rose from $1.17 billion in the second quarter of 2017 to $1.31 billion in the second quarter of 2018 due to increased demand for chromatography and mass spectrometry and electron microscopy. This increase came from the strong performance of the healthcare market channel and clinical diagnostic products.
Markit•2 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
- Market Realist•3 days ago
Estimates and Recommendations for DaVita on September 17
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.
- Zacks•6 days ago
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
The Zacks Analyst Blog Highlights: Becton, Occidental, Phillips, Allstate and Deutsche
- Zacks•7 days ago
Top Analyst Reports for Becton, Dickinson, Occidental Petroleum & Phillips 66
Top Analyst Reports for Becton, Dickinson, Occidental Petroleum & Phillips 66
- InvestorPlace•7 days ago
5 Medical Device Stocks With Impressive Staying Power
Easily the biggest trend in investing has to be healthcare stocks. From rising and aging populations in the developed world to new middle-class consumers gaining access to healthcare for the first time in emerging markets, healthcare demand is only getting bigger by the day. All in all, the combination of the two factors makes the medical device stocks some of best plays in all of healthcare.
Markit•7 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
- Market Realist•7 days ago
Thermo Fisher to Acquire BDX’s Advanced Bioprocessing Business
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company will acquire Becton Dickinson’s (BDX) advanced bioprocessing business.
- Market Realist•8 days ago
Thermo Fisher to Offer Complete Cannabis Testing Solutions
Thermo Fisher Scientific (TMO) announced on September 7, 2018, that the company offers end-to-end analytical solutions that comply with cannabis testing standards as defined by Health Canada.
- Market Realist•8 days ago
How Thermo Fisher Fared in the Second Quarter
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
- Market Realist•8 days ago
How Thermo Fisher Scientific’s Valuation Looks in September
Thermo Fisher Scientific (TMO) provides equipment, software, analytical instruments, reagents, consumables, and services. Thermo Fisher reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion, a 21.8% increase as compared to ~$5.0 billion during the second quarter of 2017. The below chart compares revenues and EPS for Thermo Fisher Scientific since the first quarter of 2017.
- InvestorPlace•8 days ago
10 Super Safe Growth Stocks to Buy for Long-Lasting Dividends
Fortunately, Simply Safe Dividends identified the 10 best dividend growth stocks that investors can rely on for secure, fast-growing income. Let’s take a look at 10 of the safest dividend stocks in the market.
Markit•9 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
Market Realist•10 days agoWhat Teleflex’s Valuation Trend Indicates
From January 2–28, 2018, Teleflex (TFX) stock rose from $254.73 to $287.65, which was its high point so far in 2018. During the broader market turmoil in February, it dipped to a low of $242.67 on March 1. Then it made a steady recovery to $280 in June but has corrected again to its current level of $248.
- Market Realist•13 days ago
Analysts Still Bullish on Teleflex Stock
Teleflex’s (TFX) interest expenses increased from $19.89 million in the second quarter of 2017 to $26.65 million in the second quarter of 2018. Its income taxes, on the other hand, decreased from $12.1 million in the second quarter of 2017 to $9.58 million in the second quarter of 2018.
Market Realist•13 days agoUnderstanding Teleflex’s Operational Performance
Teleflex’s (TFX) geographic segments include the United States, Europe, Asia, and other. Teleflex incurred a total cost of sales of $265.09 million in the second quarter of 2018 compared to $238.3 million in the second quarter of 2017. For fiscal 2018, Teleflex’s gross margins are expected to be 57.56% compared to 55.76% for fiscal 2017.
- PR Newswire•13 days ago
BD Statement on Divestiture of Advanced Bioprocessing Business
"The sale of our Advanced Bioprocessing business will create greater focus for our Life Sciences segment where BD has outstanding opportunities to contribute significant innovation for disease and therapy research and clinical diagnostics," said Patrick Kaltenbach, president of Life Sciences for BD.
- PR Newswire•13 days ago
Thermo Fisher Scientific to Acquire Advanced Bioprocessing Business from BD
WALTHAM, Mass. , Sept. 6, 2018 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has signed a definitive agreement with BD (Becton, Dickinson and Company – ...
- Reuters•15 days ago
COLUMN-U.S. court cases aim to rein in age-discrimination hiring practices
(Corrects paragraph 9 spelling to McCann instead of McGann) By Mark Miller CHICAGO, Sept 5 (Reuters) - Dale Kleber is an experienced attorney, but when he spotted an ad back in 2014 for a corporate law position at a medical device and services company that specified “no more than seven years of experience,” he applied anyway. At age 58, Kleber had extensive experience working for law firms, as an in-house general counsel and in general management jobs. Kleber’s search for senior-level general counsel positions had proved fruitless, so he widened his scope to include more junior positions.
Markit•15 days agoSee what the IHS Markit Score report has to say about Becton Dickinson and Co.
Becton Dickinson and Co NYSE:BDX
- Market Realist•17 days ago
How Becton Dickinson’s Life Sciences Segment Is Positioned
Becton Dickinson’s (BDX) Life Sciences segment, reported revenues of $1.1 billion in the fiscal third quarter of 2018 compared to $997 million in the fiscal third quarter of 2017, reflecting an ~8.2% YoY growth.
Market Realist•17 days agoAn Update on Becton Dickinson’s Medical Segments
In the fiscal third quarter, Becton Dickinson’s (BDX) Medication Management Solutions segment reported revenues of $610 million compared to $556 million in the fiscal third quarter of 2017, reflecting a ~9% YoY growth.
Market Realist•20 days agoHow Becton Dickinson Is Positioned Financially in August
Becton Dickinson (BDX) generated revenues of $4.3 billion in the fiscal third quarter compared to $1.5 billion in the fiscal third quarter of 2017, reflecting a ~41% YoY (year-over-year) growth. The acquisition of C.R. Bard primarily contributed to Becton Dickinson’s revenue growth in the third quarter.
Market Realist•20 days agoHow Analysts View Becton Dickinson in August 2018
On August 29, Becton Dickinson stock closed at $259.35, which represents a ~0.66% growth from its prior day’s close of $257.65. It hit its 52-week high of $259.99 and was a ~35% growth from its 52-week low of $191.53 on September 21, 2017.
